# An Efficacy and Safety Study of Ravulizumab in ALS Participants

> **NCT04248465** · PHASE3 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** Ravulizumab

## Key facts

- **NCT ID:** NCT04248465
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-30
- **Primary completion:** 2021-10-17
- **Final completion:** 2021-10-17
- **Target enrollment:** 382 (ACTUAL)
- **Why stopped:** The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248465, "An Efficacy and Safety Study of Ravulizumab in ALS Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04248465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*